3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
72
Breast Neoplasms
9
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Prostate Cancer Metastatic
3
Metastatic Castration Resistant Prostate Cancer
3
Bulbo-Spinal Atrophy, X-Linked
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Metastatic Hormone Sensitive Prostate Cancer
2
Melanoma
2
mCRPC
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Seizures
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Squamous Cell
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
Cannabidiol
3
perampanel
2
enzalutamide
1
Vigabatrin
1
Standard of Care
1
Levetiracetam
1
Everolimus
1
Cholecalciferol
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Seizures
×
enzalutamide
×
Clear all
NCT01977651
2024-12-06
UPWARD
Astellas Pharma Inc
Phase 4
Completed
424 enrolled
10 charts